U.S. Markets closed

Cardiovascular Systems (CSII) Catches Eye: Stock Jumps 6.9%

Zacks Equity Research

Cardiovascular Systems, Inc. CSII was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $28.39–$31.40 in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen one negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Cardiovascular Systems currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Cardiovascular Systems, Inc. Price

Cardiovascular Systems, Inc. Price | Cardiovascular Systems, Inc. Quote

Investors interested in the Medical - Productsindustry may consider Lonza Group Ag LZAGY, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is CSII going up? Or down? Predict to see what others think: Up or Down

Zacks' 10-Minute Stock-Picking Secret

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.

Learn the secret >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Lonza Group Ag (LZAGY) : Free Stock Analysis Report
 
Cardiovascular Systems, Inc. (CSII) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research